TABLE 2

Characteristics of Children in the ED With Acute Respiratory Illness Overall and by Influenza Positivity and Influenza Parent-Reported Vaccination Status, NVSN, 2018–2019

CharacteristicNo. Enrolled, n (%)Influenza-Positive, n (%)Influenza-Negative, n (%)PVaccinated (≥1 Dose), n (%)Not Vaccinated, n (%)P
Overall194442015241048896
Sex.23.12
 Male1055 (54)217 (52)838 (55)586 (56)469 (52)
 Female889 (46)203 (48)686 (45)462 (44)427 (48)
Age category<.001.004
 6 mo to <5 y1558 (80)290 (69)1268 (83)865 (83)693 (77)
 5–17 y386 (20)130 (31)256 (17)183 (17)203 (23)
Race and/or ethnicity<.001<.001
 White, non-Hispanic410 (21)58 (14)352 (23)268 (26)142 (16)
 Black, non-Hispanic799 (41)199 (47)600 (39)323 (31)476 (53)
 Other, non-Hispanic158 (8)34 (8)124 (8)100 (10)58 (6)
 Hispanic577 (30)129 (31)448 (29)357 (34)220 (25)
Underlying medical conditionsa.20.01
 ≥1548 (28)108 (26)440 (29)321 (31)227 (25)
 None1396 (72)312 (74)1084 (71)727 (69)669 (75)
Hospitalization in past year.04<.001
 01667 (86)376 (90)1291 (85)858 (82)809 (90)
 ≥1269 (14)42 (10)227 (15)185 (18)84 (9)
 Unknown8 (0)2 (0)6 (0)5 (0)3 (0)
Surveillance site.03<.001
 Cincinnati129 (7)41 (10)88 (6)49 (5)80 (9)
 Houston234 (12)48 (11)186 (12)129 (12)105 (12)
 Kansas City272 (14)45 (11)227 (15)91 (9)181 (20)
 Nashville615 (32)132 (31)483 (32)353 (34)262 (29)
 Pittsburgh286 (15)60 (14)226 (15)147 (14)139 (16)
 Rochester107 (6)29 (7)78 (5)61 (6)46 (5)
 Seattle301 (15)65 (15)236 (15)218 (21)83 (9)
Insurance status.01<.001
 Public (or none or self-pay)1570 (81)356 (85)1214 (80)805 (77)765 (85)
 Private or both352 (18)57 (14)295 (19)232 (22)120 (13)
 Unknown22 (1)7 (2)15 (1)11 (1)11 (1)
Days of symptoms since illness onset.01.16
 0–21093 (56)265 (63)828 (54)585 (56)508 (57)
 3–4491 (25)91 (22)400 (26)283 (27)208 (23)
 5–7295 (15)55 (13)240 (16)146 (14)149 (17)
 8–1065 (3)9 (2)56 (4)34 (3)31 (3)
  • a Comorbid conditions obtained from medical chart review included chronic pulmonary and/or airway, cardiac, gastrointestinal, kidney, endocrine, neurologic and/or neuromuscular, developmental, hematologic and oncologic, genetic and/or metabolic, and immunocompromised conditions; pregnancy; and prematurity.